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Aims: We have previously shown that the neurosteroid androstenediol (ADIOL)
promotes remyelination following gliotoxin-induced demyelination. However, the impact
of this ADIOL on axonal recovery is not yet known. In the present study, we investigated
the impact of ADIOL on axonal integrity following a focal demyelination in the corpus
callosum.
Methods: A 2 µl solution of either ethidium bromide (EB; 0.04%) or pyrogen-free saline
were stereotaxically injected into the corpus callosum of Sprague Dawley rats. Each of
these two rat groups was divided into two subgroups and received daily subcutaneous
injections of either ADIOL (5 mg/kg) or vehicle. The brains were collected at 2, 7 and
14 days post-stereotaxic injection. Immunofluorescent staining was used to explore
the impact of ADIOL on axonal integrity (neurofilament (NF)-M) and microglial activation
(ionized calcium binding adapter molecule 1, Iba1). The inducible nitric oxide synthase
(iNOS) and arginase-1 (arg-1), two major markers of microglial polarization towards the
proinflammatory M1 and the regulatory M2 phenotypes respectively, were monitored
using western blot.
Results: ADIOL increased the density of NF fibers and decreased the extent of axonal
damage in the vicinity of the demyelination lesion. ADIOL-induced decrease in axonal
damage was manifested by decreased number of axonal spheroids at both 2 and 7 days
post-demyelination insult. This reduced axonopathy was associated with decreased
expression of iNOS and enhanced expression of arg-1 during the acute phase.
Conclusion: These data strongly suggest that ADIOL reduces demyelination-induced
axonal damage, likely by dampening the local inflammatory response in the white matter
and shifting microglial polarization towards a reparative mode.
Keywords: axonal spheroids, neurosteroids, focal demyelination, iNOS, arginase-1
INTRODUCTION
Myelin is a lipid membrane that enwraps a large portion of axons within the nervous system. It
enhances the speed of propagation of nerve impulses and provides axons with trophic support
(Franklin et al., 2012). Within the central nervous system, this myelin sheath is produced by
oligodendrocytes (Nave, 2010a). The pathological loss of myelin (demyelination) leads to inefficient
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transmission of nerve impulses along axons such as seen in
diseases like multiple sclerosis (MS; Franklin and Gallo, 2014).
MS is a disease characterized by the development of a wide range
of disabilities depending on the area of the central nervous system
affected (Crawford et al., 2013). These deficits include sensory,
motor, autonomic and cognitive dysfunctions (Procaccini et al.,
2015). Demyelinated axons are deprived from trophic support
provided by the myelinating oligodendrocytes (Crawford et al.,
2013). The demyelination process triggers a local inflammatory
response driven largely by microglia (Franklin and Gallo, 2014).
The lack of trophic support and the accompanying inflammatory
response predispose axons to damage following demyelination
(Trapp and Stys, 2009; Stadelmann et al., 2011). Axonal injury
(axonopathy) involves disruption in axonal cytoarchitecture
and deficits in transport along the affected axons, which lead
to the development of axonal swellings (Garay et al., 2009).
Ultimately, damaged axons are broken down into condensed
spheroids and degenerate subsequently (Trapp and Stys, 2009;
Stadelmann et al., 2011). Axonopathy is considered a key
determinant of MS disease severity (Peterson and Fujinami,
2007). For example, exploration of postmortem MS brains
revealed multiple axonal transections and irregularities in the
disease-active areas (Trapp and Stys, 2009; Nave, 2010b). At
the end-stage of MS, the loss of axons in the corpus callosum
is estimated to be ∼70% (Trapp and Stys, 2009). Hence,
limiting axonal damage can potentially reduce the severity of the
disease.
Microglia, the major immune competent cells of the nervous
system, undergo activation in response to demyelination injury
(Franklin and Gallo, 2014). Activated microglia become highly
mitotic and adopt morphological changes manifested by large
perikarya and small processes (Mouihate, 2014). In addition to
these morphological changes, activated microglia acquire one
of two distinct phenotypes known as M1 and M2 phenotypes
(Miron and Franklin, 2014). M1 microglia synthesize and
release pro-inflammatory cytokines such as interleukin (IL)-1β,
IL-6, tumor necrosis factor-α (TNF-α), which promote the
proliferation and the recruitment of oligodendrocytes precursor
cells (OPCs) to the site of demyelination (Arnett et al.,
2001; Erta et al., 2012). M2 microglia on the other hand
produce anti-inflammatory cytokines including IL-4, IL-10 and
transforming growth factor-β (TGF-β), which enhance the
maturation of OPCs into myelinating oligodendrocytes (Miron
and Franklin, 2014). Morphological distinction exists between
M1 and M2 microglia. While M1 microglia show a round shape
with no apparent processes, the M2 microglial cells appear more
elongated and show short processes (Zhang et al., 2014), it is still
unclear how the M1/M2 polarization of microglia impact axonal
injury following demyelination.
We have previously shown that the dehydroepiandrosterone
metabolite known as 5-androsten-3β, 17β-diol (androstenediol
(ADIOL)), promotes the process of remyelination following
ethidium bromide (EB)-induced demyelination in the corpus
callosum of male rats (Kalakh andMouihate, 2015). In this study,
we extend our exploration to the potential effect of ADIOL
on axonal recovery following demyelination. Here we give
evidence that ADIOL reduces axonopathy following EB-induced
demyelination. These protective effects were associated with a
shift in microglial polarization from M1 to M2 phenotype at the
early stage of demyelination-induced inflammation.
MATERIALS AND METHODS
Animals
Adult male Sprague Dawley rats (250–270 g) were bred in
the Animal Resources Centre in Kuwait University. Rats were
pair-housed and left in a room with the temperature set to 22◦C
under a 12-h light-dark cycle (light is on from 7 a.m. until 7 p.m.).
The rats had access to pelleted chow and water ad libitum. This
study and experimental procedures were approved by the Animal
Research Ethics committee at the Health Sciences Centre/Kuwait
University.
Demyelination Induction
Induction of focal demyelination in rat corpus callosum was
performed as previously described (Kalakh and Mouihate,
2015). Briefly, rats were anesthetized by an intraperitoneal (i.p.)
injection of a mixture of ketamine (50 mg/Kg, i.p.) and xylazine
(5 mg/Kg, i.p.). Animals were then fixed on the stereotaxic frame
and the following coordinates were used to target the corpus
callosum: bregma: 0 mm, antero-lateral: 2 mm, dorso-ventral:
3.4 mm (Paxinos and Watson, 2006). To induce demyelination,
2 µl of 0.04% EB solution was injected into the corpus
callosum. Control animals received an equi-volume injection
of pyrogen-free saline. Delivery of the gliotoxin or saline was
performed at a rate of 1 µl/min after which the syringe was left
in place for an extra 4 min to allow the complete diffusion of the
injected solution.
Hormonal Treatment
Hormonal treatment started 2 h post-surgery. The treatment
regimen consisted of two daily subcutaneous injections of either
ADIOL (dissolved in 90% sesame oil and 10% ethanol), or
the vehicle alone. Rats were randomly assigned to receive the
treatment for periods of 2 days (acute inflammation), 7 days
(peak of demyelination) and 14 days post-surgery (beginning of
remyelination; Levine and Reynolds, 1999; Kalakh andMouihate,
2015), after which they were deeply anesthetized and sacrificed.
Tissue Collection
Animals were anesthetized using urethane (1.5 mg/Kg, i.p.)
after which transcardial perfusion was performed using ice-cold
phosphate-buffered saline (PBS). For immunofluorescence
studies, the brains were collected, post-fixed with a solution
of 10% neutral-buffered formalin, and embedded with
paraffin (Sigma Aldrich, St. Louis, MO, USA). For western
blot experiments, another set of animals were subjected to
demyelination and used to collect the affected area of the
corpus callosum by cutting the brain coronally around the
cortical landmark of the syringe entry into the brain. An area of
∼2 × 2 mm of fresh corpus callosum was collected, snap-frozen
in liquid nitrogen, and stored in −80◦C freezer for later use as
previously described (Kalakh and Mouihate, 2015).
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Immunofluorescence
Brains embedded in paraffin blocks were sectioned at a thickness
of 5 µm at the level of the lesion center and mounted on
slides for immunofluorescent staining as previously described
(Kalakh and Mouihate, 2015). Briefly, the brain sections were
deparaffinized using xylene and rehydrated through a series of
ethanol solutions. Antigen retrieval was performed by boiling
the sections in sodium citrate solution (10 mM) at a pH of
6.0 for 10 min. Microglia were detected using a polyclonal rabbit
antibody against ionized calcium binding adapter molecule 1
(Iba1; 1:2000; Wako Chemicals, USA, Inc., Richmond, VA,
USA). Microglial cells were categorized into four types (1–4)
as follows: type 1 microglia have small cell perikaryon with
long processes; type 2 microglia have relatively larger perikaryon
with short processes; type 3 microglia have irregularly shaped
and enlarged cell body with very few short processes; and
type 4 microglia show an ameboid shape with no apparent
processes. Type 4 microglia are morphologically similar to
M1 microglia, while M2 microglia is akin to type 2 (Giulian,
1987; Zhang et al., 2014). Neuronal axons were detected using
a polyclonal goat anti-medium neurofilament (NF) antibody
(1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
myelin sheath was detected using a mouse monoclonal antibody
against myelin basic protein (MBP; 1:2000, Calbiochem, Billerica,
MA, USA). The following day, brain sections were washed with
PBS solution 3× for 10 min each and incubated with appropriate
polyclonal donkey secondary antibodies anti-mouse, anti-rabbit,
or anti-goat tagged with either Alexa 488 or Alexa 555 (1:1000)
for 2 h at room temperature. The secondary antibodies were
then washed off with PBS (3X, 10 min each). Brain sections were
then mounted with a mounting medium and covered with a
coverslip.
Images of the immunofluorescently stained sections were
observed using Zeiss LSM 700 confocal microscope (Carl Zeiss,
Göttingen, Germany). Images of areas of interest were acquired
using AxioVision software (Carl Zeiss, Gottingen, Germany)
with 40× or 63× objectives. For the analysis of NF staining,
images of right and left edges of the lesion were acquired from
three consecutive sections originating from 4 to 10 different rats.
The density of NF+ fibers was analyzed by randomly selecting
three different areas of each acquired image. The selected areas
were binarized and the area covered by NF+ fibers was measured
as percentage of the total area as previously described (Kalakh
andMouihate, 2015). For axonal spheroid analysis, each spheroid
appearing in the field was circled and its area was measured using
ImageJ software (Schneider et al., 2012). A total of∼12150 axonal
spheroids were analyzed for all different treatment time points.
For microglial cell count, images from the center of the lesion
were acquired. Three consecutive brain sections from four to six
different rats were used for counting using the cell counter macro
in ImageJ software. All the above analyses were performed by an
observer blind to the treatment received by each rat.
Transmission Electron Microscopy
Transmission electron microscopy (TEM) was performed as
previously described (Kalakh and Mouihate, 2015). Seven
days post-demyelination, rats given either ADIOL or vehicle
(EB-O; n = 5, EB-A; n = 5) were anesthetized using urethane
(1.5 mg/Kg, i.p.) and perfused with ice-cold PBS. The injected
area was collected by cutting the brain sagittally around
the needle track mark under a dissecting microscope. The
collected tissue was then post-fixed in 3% glutaraldehyde
for 3 h after which they were post-fixed for 2 h in 1%
osmium tetroxide. The tissue was then dehydrated using
increasing concentrations of ethanol and embedded with epoxy-
resin. Semi-thin sections (0.5 µm) were obtained using a
glass knife mounted on an ultramicrotome. The semi-thin
sections were stained with 1% toluidine blue and observed
under light microscope (Zeiss Axio Observer A1) to ensure
the presence of the lesion in the collected tissue. Tissue
blocks were then cut in ultrathin sections (100 nm), mounted
on copper grids, and stained with uranyl acetate and lead
citrate for TEM observation as previously described. Images
were acquired using 10,000× objective (JEOL’s JEM-1200
EXII Scanning Transmission Electron Microscope, Tokyo,
Japan).
Western Blot
Protein extraction from brain tissue was performed as previously
described (Mouihate et al., 2004; Kalakh and Mouihate, 2015).
Briefly, the brain tissue was homogenized in a lysis buffer (MOPS,
20 mM; KCl, 150 mM; Mg Acetate, 4.5 mM; Triton X, 1%)
containing protease inhibitor cocktail tablet (Roche Applied
Science, Mannheim, Germany) and centrifuged at 12,000 g for
15 min at 4◦C. The supernatant containing the proteins was then
collected and protein levels were assayed using bicinchoninic
acid protein assay (Pierce Chemical Co., Rockford, IL, USA).
Proteins (60 µg per well) were separated using 12% SDS
PAGE, transferred into a nitrocellulose membrane, and then
incubated with primary mouse monoclonal antibodies anti-
inducible nitric oxide synthase (iNOS; M1 microglia, 1:1000, BD
Biosciences, CA, USA) or anti-arginase-1 (arg-1; M2 microglia,
1:1000, BD Biosciences, CA, USA). The following day, the
membranes were washed and incubated with a secondary
horseradish-peroxidase conjugated donkey anti-mouse antibody
(1:2000, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
at room temperature for 2 h. A chemiluminescent substrate
(ECL kit; GE Healthcare, UK) was applied to the membrane
and proteins were detected using a Kodak X-Omat film
(Eastman Kodak, New York, NY, USA). The membranes were
then ‘‘stripped’’ off the first set of primary and secondary
antibodies using β-mercaptoethanol (Sigma Aldrich, St. Louis,
MO, USA) and re-incubated with primary rabbit antibody
anti-actin (a house keeping protein; 1:10, 000, Sigma Aldrich,
St. Louis, MO, USA). Actin protein was detected as described
earlier.
Semi-quantitative estimation of protein levels was performed
using ImageJ software. The optical density (OD) profile was
obtained for each protein band. The area under the curve (AUC)
of the OD profile was used to estimate the protein levels in each
sample. The ratio of AUC values of iNOS/actin or arg-1/actin
was determined and used for comparison between experimental
groups.
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 February 2017 | Volume 11 | Article 49
Kalakh and Mouihate Androstenediol Dampens Demyelination-Induced Axonopathy
Statistics
Immunofluorescence data of axonal damage and western blot
were compared using unpaired student’s t test. Data for
percentage area of total NF were compared using ANOVA
followed by Newman Keuls post hoc test. Analysis of the
frequency distribution of axonal spheroids was performed using
Kolmogorov–Smirnov test (K-S test). Analysis of microglial
activation using immunofluorescence was performed using
two-way ANOVA followed by Bonferroni post hoc test. A p value
of less than 0.05 was considered statistically significant. All data
are presented as mean± SEM.
RESULTS
ADIOL Reduced Axonal Damage at the
Acute Stage of Demyelination
A prominent axonal damage was evident in the vicinity of
the corpus callosum 2 days post-demyelination insult as a
result of EB injection. Signs of axonopathy included multiple
axonal transections and swellings indicative of disrupted axonal
cytoskeleton (Figure 1A middle panel, arrows). These signs
were not present in saline-injected corpus callosum, which
showed a healthy pattern of myelinated axons (Figure 1A upper
panel). To assess the extent of axonal loss in the demyelinated
corpus callosum, we measured the percentage area covered by
NF+ fibers at both edges of the lesion. Compared to saline-
injected corpus callosum, EB-injected corpus callosum showed
a significant reduction in the density of NF+ fibers (Sal-O;
n = 4, EB-O; n = 4, p < 0.05; Figure 1A upper panel,
Figure 1B). However, there was no difference in the area fraction
covered by NF+ fibers between oil-treated and ADIOL-treated
groups (EB-O; n = 4, EB-A; n = 6, p > 0.05; Figures 1A,B).
We also monitored the number of axonal spheroids per area
(density) which are indicative of axonal damage (Sternberger and
Sternberger, 1983). Treatment with ADIOL reduced the density
of these axonal spheroids in the vicinity of the demyelination
lesion when compared to those seen in oil-treated animals
(EB-O; n = 6, EB-A; n = 6, p < 0.05; Figures 1A,C).
Other pathological features were also observed such as axons
with detached myelin sheath and disorganized myelin sheaths
(Figure 1A middle panel, arrowheads). ADIOL-treated animals
on the other hand showed a higher density of axons with healthy-
looking myelin sheaths around them (Figure 1A lower panel,
arrowheads).
We further measured the sizes of axonal spheroids in the
vicinity of the demyelinated area of the corpus callosum and
plotted their frequency distribution (Figure 1D). The majority
of axonal spheroids seen at 2 days post-EB injection had sizes less
than 2.5 µm2. Both ADIOL-treated and oil-treated animals had
the highest frequency of axonal spheroids at sizes ∼0.5–1 µm2.
The large axonal spheroids ( >2.5 µm2) were less frequent in
the vicinity of demyelinated area of the corpus callosum of rats
injected with ADIOL when compared to those seen in vehicle-
treated rats. Statistical analysis using K-S test showed a significant
difference in the frequency distribution of axonal spheroids
between oil-treated and ADIOL-treated groups (EB-O; n = 6,
EB-A; n = 6, p< 0.0001, D = 0.252).
ADIOL Reduced Axonal Damage at the
Peak of Demyelination
The integrity of axonal fibers was also assessed at the peak of
demyelination which corresponds to 7 days post-EB injection.
The injection of EB into the corpus callosum resulted in a
decrease in the percentage area covered by NF+ fibers (Figure 2A
middle panel) compared to the saline-injected corpus callosum
(Sal-O; n = 4, EB-O; n = 5, p < 0.05; Figure 2A upper panel,
Figure 2B). We have noticed that oil-treated animals showed
multiple irregular NF+ spheroids (Figure 2A middle panel).
Injection of ADIOL resulted in a significant increase in the
density of NF+ fibers at the edges of the demyelination lesion
compared to oil-treated animals (EB-O; n = 5, EB-A; n = 8,
p < 0.05; Figure 2A lower panel and Figure 2B). This enhanced
axonal density was accompanied by a reduction in the density of
axonal spheroids in the vicinity of EB-injected corpus callosum
(EB-O; n = 6, EB-A; n = 10, p < 0.05; Figure 2C). We also
detected a significant difference in the frequency distribution
of spheroids between oil-treated and ADIOL-treated groups
(p < 0.0001, D = 0.087). The majority of axonal spheroids
seen 7 days post-EB injection had sizes ranging from 1 µm2 to
7.5 µm2. These spheroids were less frequent in the vicinity of
corpus callosum of rats given ADIOL when compared to those
seen in vehicle-injected rats (Figure 2D). Because ADIOL had a
stronger effect on axonal spheroids at the peak of demyelination,
we explored the untrastructural change at the interface between
the axons and the myelin sheet. Using TEM, we observed that
there was a larger number of myelinated axons in the corpus
callosum of rats given ADIOL when compared to those of
rats given oil (Figure 2E). Furthermore, the detachment of
myelin sheath from the axons was more frequently seen in the
EB-injected corpus callosum of vehicle injected rats (Figure 2E,
arrowheads).
ADIOL’s Impact on Axonal Damage at the
Initial Stage of Remyelination
The lesion was also monitored 14-days post-EB injection, a time
point that corresponds to the start of the remyelination process.
Compared to saline-injected corpus callosum, EB injection
resulted in a reduction in the density of NF+ fibers at the
edges of the lesion. ADIOL enhanced the density of NF+ fibers
14 days post-EB injection when compared to vehicle-treated
animals (EB-O; n = 4, EB-A; n = 5, p < 0.01; Figure 3A).
However, there was no significant difference in the total
number of axonal spheroids at the edge of the lesion between
the two experimental groups (EB-O; n = 4, EB-A; n = 4,
p> 0.05; Figure 3B). Interestingly, axonal spheroids of relatively
smaller sizes (1.5 µm2–3.5 µm2) were relatively less frequent
in the EB-injected corpus callosum of rats given ADIOL when
compared to those of vehicle-injected rats (p< 0.0001,D = 0.078;
Figure 3C).
ADIOL’s Impact on Microglial Activation
and Polarization Post-Demyelination Insult
We have previously reported that ADIOL treatment resulted in
a reduction in the total number of activated microglia present
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FIGURE 1 | Effect of androstenediol (ADIOL) on axonal damage 2 days post-ethidium bromide (EB)-induced demyelination. (A) Immunofluorescent
staining of neurofilament (NF, green) and myelin basic protein (MBP, red) in the corpus callosum of Sal-O, EB-O or EB-A rat groups. Injection of EB into the corpus
callosum (EB-O panel) decreased the density of NF+ fibers when compared to that seen in saline-injected group (Sal-O panel). Systemic injection of ADIOL increased
the density of NF+ fibers in the vicinity of the demyelinated corpus callosum (EB-A panel) compared to the one seen in EB-O rat group. At the edge of the
demyelination lesion, many of NF+ axons in EB-O rat group either lacked myelin (arrows) or had a detached myelin sheath (arrowheads). In contrast, the axons of
EB-A rat group had more compact myelin sheaths (arrowheads). (B) Bar graph shows the percentage area covered by NF+ fibers in the three rat groups (Sal-O:
n = 4, EB-O: n = 4, EB-A: n = 6). EB injection induced a significant decrease in the area covered by NF+ fibers when compared to NF+ density in saline-injected
animals (p < 0.001). This decreased axonal density was not affected by systemic injection of ADIOL. (C) Bar graph presents the number of axonal spheroids in the
vicinity of the demyelination lesion in EB-O and EB-A groups. ADIOL significantly reduced the number of axonal spheroids compared to oil-treated animals (EB-O:
n = 4, EB-A: n = 6, p < 0.05). (D) Histogram shows the frequency distribution of axonal spheroids according to their sizes. The majority of axonal spheroids had a
size less than 2.5 µm2 in both EB-O and EB-A rat groups. ∗p < 0.05, ∗∗∗p < 0.001. All data are presented as mean ± SEM. Scale bar = 50 µm.
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FIGURE 2 | Effect of ADIOL on axonal damage 7 days post-EB-induced demyelination. (A) Immunofluorescent staining of NF (green) and MBP (red) in
corpus callosum 7 days post-EB injection. EB injection resulted in a reduction in the density of NF+ fibers in the EB-O group (EB-O panel) compared to rat group
given intra-corpus callosum injection of saline (Sal-O panel). Axonal spheroids indicative of axonal damage are more frequently observed in the EB-O group (EB-O
panel) compared to the EB-A group (EB-A panel). (B) Bar graph presents the percentage area covered by NF+ fibers. EB injection significantly reduced the density of
NF+ fibers in the vicinity of the demyelinated corpus callosum when compared to saline-injected animals (Sal-O: n = 4, EB-O: n = 5, EB-A: n = 8, p < 0.001). ADIOL
treatment significantly increased the density of NF+ fibers compared to that seen in EB-O rat group (p < 0.05). (C) Bar graph shows the count of axonal spheroids in
the vicinity of the EB-induced lesion. ADIOL significantly reduced the number of these spheroids compared to oil-treated animals (EB-O: n = 6, EB-A: n = 10,
p < 0.05). (D) The histogram shows the frequency distribution of axonal spheroids according to their sizes. Most spheroids observed were of sizes ranging from
1 µm2 to 7.5 µm2. ADIOL reduced the frequency of these spheroids in the vicinity of corpus callosum when compared to oil-treated rats. (E) Transmission electron
micrographs of the EB-injected corpus callosum of oil-treated and ADIOL-treated animals. Signs of myelin sheath detachment from axons are more apparent in the
oil-treated animals (arrowheads in the upper micrograph) compared to those seen in ADIOL-treated ones (lower micrograph). ∗p < 0.05, ∗∗∗p < 0.001. All data are
presented as mean ± SEM. Scale bar for immunofluorescence images = 50 µm. Scale bar for transmission electron microscopy (TEM) images = 1 µm.
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FIGURE 3 | Effect of ADIOL on axonal damage and microglial
activation 14 days post-demyelination. The bar graph in (A) shows the
density of NF+ fibers in the vicinity of the demyelination lesion of the corpus
callosum 14 days post-EB injection in Sal-O, EB-O and EB-A rat groups. EB
injection into the corpus callosum led to a significant reduction in the density
of NF+ fibers in the vicinity of the lesion when compared to the saline-injected
group (Sal-O; n= 4, EB-O; n = 4, p < 0.001). In EB injected corpus callosa,
the systemic injection of ADIOL induced a significant increase in the density of
NF+ fiber compared to control animals given systemic injection of oil
(p < 0.01; EB-O; n = 4, EB-A; n = 5, p < 0.01). Axonal spheroids count in the
vicinity of the demyelination lesion are presented in (B). Administration of
ADIOL did not significantly affect the total number of axonal spheroids (EB-O;
n = 4, EB-A; n = 4, p > 0.05). Histogram in (C) shows the frequency
distribution of axonal spheroids according to their size. Most axonal spheroids
observed were of sizes ranging from 1.5 µm2 to 3.5 µm2. Axonal spheroids of
sizes less than 3.5 µm2 were less frequent in the vicinity of the demyelination
lesion of corpus callosum of rats given ADIOL when compared to those given
vehicle. ∗∗p < 0.01, ∗∗∗p < 0.001. All data are presented as mean ± SEM.
at the edges of EB-induced demyelination lesion (Kalakh and
Mouihate, 2015). In this study, we focused our exploration
on microglial activation at the center of the lesion. The
perikarya of activated microglia become gradually bigger and
their branches become smaller. Fully activated microglia adopt
a round shape with no apparent processes. We monitored
microglia at four different stages of activation at the center of
the demyelination lesion (Figure 4A) and compared their cell
density between vehicle-treated and ADIOL-treated animals at
2 (Figure 4B), 7 (Figure 4C) and 14 days post-demyelination
insult. We observed a significant overall change in the cell
density of type 1 microglia as a function of time (F(2,20) = 8.506,
p = 0.0021). Post hoc analysis showed that ADIOL administration
led to a significant increase in the cell density of type 1 microglia
14 days post-demyelination lesion when compared to those
microglia seen at 2 days post-demyelination lesion (p < 0.01;
Figure 4D). However, there was no significant effect of ADIOL
on the cells density of type 1 microglia at any individual time
point.
We observed a significant overall change in the cell density of
type 2microglia as a function of time (F(2,20) = 16.54, p< 0.0001).
Post hoc analysis showed that there was a significant increase in
the cell density of these cells in the EB-O group 14 days post-
demyelination insult when compared to those seen at 2 days
(p< 0.05) and 7 days after EB injection (p< 0.05; Figure 4E).
Administration of ADIOL led to a significant increase in the
cell density of type 2 microglia 14 days post-demyelination when
compared to that seen at 2 days (p< 0.001) and 7 days (p< 0.001)
after demyelination insult. However, there was no significant
effect of ADIOL on the cell density of type 2 microglia at each
individual time point.
Cell density analysis of type 3 microglia showed an overall
significant change over time (F(2,20) = 90.37, p< 0.0001). Post hoc
analysis revealed that there was a significant increase in the cell
density of type 3 microglia 7 days post-demyelination injury
when compared to 2 days (p < 0.0001) and 14 days (p < 0.0001)
in both EB-O and EB-A groups (Figure 4F).
Cell density analysis of type 4 microglia showed an overall
significant change over time (F(2,20) = 259.4, p< 0.0001). Post hoc
analysis showed a significant increase in the cell density of type
4 microglia at 7 days post-demyelination injury when compared
to the cell density seen at either 2 days (p < 0.0001) or 14 days
(Figure 4G; p < 0.0001) after demyelination lesion. However,
there was no significant effect of ADIOL on the cells density of
type 4 microglia at any individual time point.
We also assessed whether ADIOL treatment affects microglial
polarization into either M1 or M2 phenotypes by monitoring
the expression levels of iNOS (M1) and arg-1 (M2). Two days
post-demyelination lesion, the expression level of iNOS was
significantly reduced in the EB-injected area of the corpus
callosum of rats given ADIOL when compared to those injected
with the vehicle (EB-O; n = 4, EB-A; n = 4, p < 0.05;
Figures 5A,C). Injection of ADIOL also led to an increase in
the expression levels of M2 marker arg-1 (EB-O; n = 4, EB-A;
n = 4, p< 0.05; Figures 5A,D). In addition, ADIOL did not affect
the expression of either iNOS expression (M1 marker) or arg-1
expression (M2 marker) at either 7 days (EB-O; n = 4, EB-A;
n = 4, p > 0.05; Figures 5B,E,F) or 14 days post-demyelination
insult (EB-O; n = 3, EB-A; n = 3, p> 0.05; Figures 5G,H).
DISCUSSION
We have previously shown that ADIOL dampened EB-induced
demyelination lesion, promoted the proliferation andmaturation
of oligodendrocyte progenitor cells in the demyelinated area,
and enhanced the phosphorylation of MBP. These processes are
all essential for a successful remyelination process (Kalakh and
Mouihate, 2015). Here, we focused on ADIOL’s neuroprotective
properties on axonal integrity following demyelination by
exploring its impact on the inflammatory milieu triggered
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FIGURE 4 | Impact of ADIOL on microglial activation following EB injection into the corpus callosum. Micrographs in (A) show the different stages of
microglial activation used in the morphological analysis. Type 1 microglia have a small perikaryon and long processes. Type 2 microglia have larger cell perikaryon
and shorter processes than type 1 microglia. Type 3 microglia have a large round cell body and multiple shorter branches, while type 4 has a round cell body with no
apparent processes. Micrographs in (B,C) show microglial cells at the center of EB-injected corpus callosum at 2 days and 7 days respectively. Graph bars show cell
counts of microglia of type 1 (D), type 2 (E), type 3 (F) and type 4 (G), at 2, 7 and 14 days post-demyelination lesion. There was no significant effect of ADIOL on
type 1 microglia at any given time point (D). ADIOL administration led to a significant increase in microglial cell counts at 14 days post-EB-injection when compared
to those seen at 2 days (p < 0.01). The number of type 2 microglia was significantly higher at 14 days post-lesion in both oil-treated (p < 0.05) and ADIOL-treated
(p < 0.001) rat groups (E). Both type 3 and type 4 microglia peaked at 7 days post-lesion to a significantly higher level when compared to that of 2 days and 14 days
rat groups. Such increase was observed in rats given either ADIOL or oil (p < 0.0001; F,G). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗ p < 0.0001. All data are
presented as mean ± SEM. Scale bar = 50 µm.
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FIGURE 5 | Impact of ADIOL on microglial polarization post-EB
injection. Micrographs in (A,B) show inducible nitric oxide synthase (iNOS),
arginase-1 (Arg-1) and actin protein expression in the corpus callosum area
damaged by EB in rats given a systemic injection of either oil (EB-O) or ADIOL
(EB-A) for 2 and 7 days respectively. The bar graphs present semi-quantitative
analysis of western blot data at 2 day (C,D), 7 days (E,F) and 14 days (G,H)
after the injection of EB into the corpus callosum. Systemic injection of ADIOL
for 2 days resulted in a significant reduction in the expression level of iNOS
(A,C) when compared to its corresponding levels in EB-O rat group (EB-O;
n = 4, EB-A; n = 4, p < 0.05). ADIOL injection for 2 days led to a significant
increase in the expression level of Arg-1 protein (A,D) when compared to that
seen in EB-O rat group (EB-O; n = 4, EB-A; n = 4, p < 0.05). ∗p < 0.05 at
7 days post-EB injection, the expression levels of iNOS (B,E) or Arg-1 (B,F)
proteins were not affected by systemic injection of ADIOL (EB-O; n = 4, EB-A;
n = 4, p > 0.05). Similarly, at 14 days after EB injection the expression levels of
iNOS (G) or Arg-1 (H) proteins were not affected by systemic injection of
ADIOL (EB-O; n = 3, EB-A; n = 3, p > 0.05). ∗p < 0.05. All data are presented
as mean ± SEM.
by the demyelination insult. In this study, we have made
a number of novel observations regarding the protective
effect of the neuroactive steroid ADIOL on axonal integrity
following a localized demyelination lesion in the corpus
callosum: (1) systemic administration of ADIOL reduced axonal
abnormalities (i.e., axonal spheroids) following EB-induced focal
demyelination in the corpus callosum; and (2) axonal protection
was associated with dampened inflammatory response that was
shifted towards the neuroprotective M2 phenotype during the
acute phase.
To our knowledge, this is the first study to explore how
ADIOL affects axonal recovery following focal demyelination.
Previous studies have assessed the promyelinating effect
of ADIOL were performed using experimental autoimmune
encephalomyelitis (EAE), an experimental model with an
overt activation of the immune system (Nicoletti et al., 2010;
Saijo et al., 2011; Hanna et al., 2015). In this study, we
induced demyelination within a small area of the corpus
callosum to minimize the contribution of systemic immune
response in the recovery process. This experimental model
allows the investigation of ADIOL’s effect on the local
inflammatory response and how it affects axonal recovery
following demyelination. Furthermore, the time course for the
acute phase (2 days post-EB injection) and peak of demyelination
(7 days post-EB injection) as well as the starting time for
the remyelination (14 days post-EB injection) has been well
characterized in this experimental model (Levine and Reynolds,
1999; Gregg et al., 2007; Kalakh and Mouihate, 2015, 2016).
Axonal Damage Following Demyelination
Axonal damage is a pathological sign of a number of
neurodegenerative conditions including MS (Trapp and Stys,
2009; Haines et al., 2011), stroke and brain/spinal traumatic
injuries (Czeiter et al., 2008; Hinman, 2014). Postmortem studies
on brains of MS patients showed extensive axonal irregularities
and transections in disease-active areas of the brain (Trapp and
Stys, 2009; Nave, 2010b). The extent of axonal damage is a
major determinant of disease severity (Lingor et al., 2012). In the
present study we have assessed the condition of axonal damage
in the vicinity of the demyelination lesion at 2, 7 and 14 days
post-EB injection. Our data showed that EB injection into the
corpus callosum reduces the density of axons present at the edge
of the lesion from ∼70% in the control animals to ∼30% by
the second day post-demyelination insult. This percentage was
further reduced to as low as∼8% by the seventh day post-lesion.
A spontaneous recovery in axonal density was seen 14 days post-
lesion.
Several line of evidence suggests that ADIOL exerted an
axono-protective effect. Indeed ADIOL increased the density
of axons at the edge of the demyelination lesion by the
seventh day of treatment from ∼10% in oil-treated animals
to ∼20%. This recovery of axons was further increased by
day 14 post-demyelination insult. Furthermore, ADIOL reduced
the number of axonal spheroids present at the vicinity of
demyelinated area by 2 and 7 days post-gliotoxin injection. At
the ultrastructural level, administration of ADIOL enhanced the
percentage of remyelinated axons in the vicinity of the lesion
as we have previously shown (Kalakh and Mouihate, 2015). In
addition, degenerating axons were less frequently observed in
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these animals. ADIOL also decreased the g-ratio of remyelinated
axons, which indicates better recovery following demyelination
(Kalakh and Mouihate, 2015).
ADIOL Effect on Inflammation-Induced
Axonal Damage
Axonal damage is largely influenced by the inflammatory
response associated with demyelination (Lingor et al., 2012).
Understanding how inflammation affects demyelinated
axons can help in developing treatments to overcome
demyelination-associated axonopathy and therefore reduce
disease severity. The environment of EB-induced demyelination
is very complex and includes the damaged cells, injured
axons, myelin fragments remaining from demyelinated
axons and reactive glia (microglia, astrocytes; Horn et al.,
2008). Using immunofluorescence and electron microscopy,
we observed the presence of multiple axonal transections,
axonal spheroids, empty myelin sheaths, and disintegrated
and de-compacted myelin sheaths. The inflammatory
cascade is initiated in response to this damage in which
microglia are crucial players (Levine and Reynolds, 1999).
We observed a moderate microglial activation by 2 days
post-lesion which peaked 7 days post-lesion. Microglial
activation is required for clearing out cellular debris and
myelin fragments in the lesion area. This protective effect
of microglia appear to create conducive environment for
the remyelination process (Pohl et al., 2011; Lampron et al.,
2015). We have classified activated microglia based on their
morphology into four types (described earlier). At 2 days
post-demyelination insult, a large proportion of microglia
adopted activated morphologies (types 2, 3 and 4) indicating
the high responsiveness of these cells to the lesion during
the acute phase. Such activation of microglia was stronger
on the 7th day post-demyelination insult, especially for
type 3 and type 4 microglia. Two weeks post-EB-lesion, the
cell density of these activated microglia was significantly
reduced to levels seen during the acute phase (2 days). This
observation is in line with previously published data which
established that the maximal brain inflammation occurs
7 days post-EB-induced demyelination insult, while the
remyelination process is initiated spontaneously at around
14 days post-EB injection (Levine and Reynolds, 1999). We
did not observe a significant effect of ADIOL on the cell
density of activated microglia at any given time point. However,
ADIOL administration for 14 days led to a slightly but a
significantly increase in the cell density of type 1 microglia.
Because morphologically this microglial cell type is assimilated
with a ‘‘resting’’ state, it is possible that ADIOL enhances the
process of remyelination (Kalakh and Mouihate, 2015) by
modulating the activation level of a subset of microglia. Future
studies will explore the intracellular mechanisms underlying
the effect(s) of ADIOL on microglia during the remyelination
phase.
One incessant question is whether peripheral macrophages
contribute to the observed Iba1+ cells, we traditionally attribute
to resident microglia. Owing to their morphologies and the
existence of the remnant of processes in type 2 and 3
microglial types, it is unlikely that these two cell types are
derived from peripheral macrophages, as the peripherally
derived macrophages have been shown to be spherical in
shape when they invade an affected tissue (Greenhalgh and
David, 2014). However, what we have considered as type
4 microglia adopt a round shape that is undistinguished from
peripheral macrophages. Thus there is a possibility that these
cells are peripheral macrophages. However, there are indications
that the early microglias are the major contributors to brain
inflammation during the acute phase (less than 3 days; Horn
et al., 2008; Olah et al., 2012).
In addition to the classification of microglia based on their
morphological changes, activated microglia are also categorized
into either M1 andM2 phenotypes. These microglia can produce
either pro-inflammatory cytokines such as IL-1ß and TNF-α
(M1 microglia), or anti-inflammatory cytokines such as IL-10
and TGF-ß (M2 microglia; Neumann et al., 2009). Axonal
damage is worsened by proinflammatory cytokines produced by
M1 microglia. Regulatory factors produced by M2 microglia,
on the other hand, appear to play a neuroprotective for axons
following demyelination (Cherry et al., 2014). Therefore, the
dynamics of M1 and M2 microglial response are important for
axonal recovery following demyelination. In our experiment,
we found that EB injection into the corpus callosum resulted,
at least during the acute phase, in enhanced expression of the
M1 marker iNOS and decreased expression of the M2 marker
Arg-1. As previously mentioned, ameboid-shaped microglia are
likely of M1 phenotype (Zhang et al., 2014). Thus, it appears
that ADIOL reduces M1 phenotype. Such inflammatory milieu
is likely setting the stage for the extensive axonal damage
at later time points. This M1 bias was significantly reverted
when the rats were given systemic injection of ADIOL. This
ADIOL-induced change in microglial bias towards M2 types
strongly suggests that ADIOL promotes a shift in microglial
activation, especially during the early phase of demyelination
insult. Such microglial shift was lost when microglia were
assessed at later stages of the demyelination process (7 and
14 days post-demyelination insult). It is noteworthy that we
conducted a series of immunostaining to determine the cellular
distribution of M1 and M2 markers in the demyelination
lesion area. In our hands, the available antibodies against
iNOS and arg-1 did not show a convincing staining at
the site of the lesion of the rat corpus callosum (data not
shown). As mentioned above, it is possible that the early
stage of polarization is driven, at least in part, by peripheral
macrophages. However, this possibility is less likely as the
early phase of neuroinflammation is mainly driven by resident
microglia (Horn et al., 2008; Olah et al., 2012; Greenhalgh
and David, 2014). Therefore, it is possible that microglial
polarization observed at 2 days post-lesion is driven mainly
by resident microglia, while at later stages (7 or 14 days
post-demyelination insult), the robust infiltration of peripheral
macrophages does not allow the detection of clear microglial
phenotype. These findings are in line with previous studies
which have shown that pretreatment with ADIOL (2 days before
lesion) reduced the levels of iNOS and the proinflammatory
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cytokines TNF-α and IL-6 in the striatum in an animal model
of Huntington’s disease (Hanna et al., 2015). ADIOL was also
shown to modulate inflammation towards Th2 response and
increase the level of the anti-inflammatory cytokine IL-4 in
EAE, an autoimmune model of demyelination (Auci et al.,
2005).
CONCLUSION
We give the first evidence that ADIOL reduces signs of
axonopathy following EB-induced focal demyelination. Our
present and previously published work suggests that ADIOL
is endowed with promyelinating and neuroprotective effects.
ADIOL appears to exert these beneficial effects by directing
microglial activation towards a regulatory pathway, at least
during the acute phase. The data presented in this study
opens new research avenues for the potential therapeutic
effect of ADIOL in the reduction of demyelination-induced
axonopathy.
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